Investigational 4-Antigen Staphylococcus aureus vaccine fails to prevent infections in spinal surgery

The summary of the research is as follows:

• The Study enrollment was halted when a prespecified interim efficacy analysis met predefined futility criteria.
• SA4Ag was not efficacious in preventing postoperative S aureus infection.
• There were similar Colonization rates across groups through postoperative Day 180.
• Mild to moderate Local reactions and systemic events were recorded.
• The frequencies of Adverse events were similar in the groups.

Concluding further, SA4Ag was safe and well tolerated. Though it elicited antibody responses that blocked key S aureus virulence mechanisms, it was ineffective in preventing S aureus infection in those undergoing spinal fusion procedures.

Further reading:

Hassanzadeh H, Baber J, Begier E, Noriega DC, Konishi H, Yato Y, Wang MY, Le Huec JC, Patel V, Varga P, Liljenqvist U, Conly J, Sabharwal C, Munjal I, Cooper D, Radley D, Jaques A, Patton M, Gruber WC, Jansen KU, Anderson AS, Gurtman A; STRIVE Investigator Team. Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STRIVE Randomized Clinical Trial. Clin Infect Dis. 2023 May 1:ciad218. doi: 10.1093/cid/ciad218.